Teva Pharma Industries Ltd ADR (TEVA) financial statements
Teva Pharma Industries Ltd ADR reported revenue of $17.3B in fiscal 2025, down 2.6% a year over 9 years.
Net income was $1.4B and the operating margin 12.5%, against 9.8% in 2016.
Free cash flow was $1.1B.
The diluted share count rose 121019671% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Teva Pharma Industries Ltd ADR's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.9B | $21.9B | $18.3B | $16.9B | $16.7B | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Cost of revenue | $10.2B | $11.2B | $10.0B | $9.4B | $8.9B | $8.3B | $8.0B | $8.2B | $8.5B | $8.3B |
| Gross profit | $11.7B | $10.6B | $8.3B | $7.5B | $7.7B | $7.6B | $7.0B | $7.6B | $8.1B | $8.9B |
| Research and development | $2.1B | $1.8B | $1.2B | $1.0B | $997M | $967M | $838M | $953M | $998M | $1.0B |
| Selling, general and admin | $5.0B | $4.8B | $4.2B | $3.8B | $3.7B | $3.5B | $3.4B | $3.5B | $3.7B | $4.0B |
| Operating income | $2.2B | -$17.5B | -$1.6B | -$443M | -$3.6B | $1.7B | -$2.2B | $433M | -$303M | $2.2B |
| Interest expense | $546M | $875M | $920M | $822M | $901M | $891M | $930M | $1.0B | $1.0B | $916M |
| Pre-tax income | $824M | -$18.4B | -$2.6B | -$1.3B | -$4.4B | $658M | -$3.2B | -$624M | -$1.3B | $1.2B |
| Income tax | $521M | -$1.9B | -$195M | -$278M | -$168M | $211M | -$643M | -$7M | $676M | -$180M |
| Net income | $329M | -$16.3B | -$2.1B | -$999M | -$4.0B | $417M | -$2.4B | -$559M | -$1.6B | $1.4B |
| EPS (diluted) | $0.07 | -$16.26 | -$2.35 | -$0.91 | -$3.64 | $0.38 | -$2.20 | -$0.50 | -$1.45 | $1.21 |
| Diluted shares | 0M | 1.02B | 1.02B | 1.09B | 1.09B | 1.11B | 1.11B | 1.12B | 1.13B | 1.16B |
| Gross margin | 53.2% | 48.6% | 45.4% | 44.6% | 46.4% | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| Operating margin | 9.8% | -80.0% | -9.0% | -2.6% | -21.4% | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% |
| Net margin | 1.5% | -74.4% | -11.8% | -5.9% | -24.0% | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
Balance sheet
Fiscal years, from Teva Pharma Industries Ltd ADR's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $988M | $963M | $1.8B | $2.0B | $2.2B | $2.2B | $2.8B | $3.2B | $3.3B | $3.6B |
| Receivables | $7.5B | $7.1B | $5.8B | $5.7B | $4.6B | $4.5B | $3.7B | $3.4B | $3.1B | $3.7B |
| Inventory | $5.0B | $4.9B | $4.7B | $4.4B | $4.4B | $3.8B | $3.8B | $4.0B | $3.0B | $3.2B |
| Total current assets | $17.2B | $15.4B | $13.8B | $13.5B | $13.0B | $12.6B | $12.1B | $12.5B | $12.6B | $13.9B |
| Property, plant and equipment | $8.1B | $7.7B | $6.9B | $6.4B | $6.3B | $6.0B | $5.7B | $5.8B | $4.6B | $4.1B |
| Goodwill | $44.4B | $28.4B | $24.9B | $24.8B | $20.6B | $17.6B | $17.2B | $17.2B | $16.0B | $16.0B |
| Total assets | $93.1B | $70.6B | $60.7B | $57.5B | $50.6B | $47.7B | $44.0B | $43.5B | $39.3B | $40.7B |
| Total current liabilities | $18.5B | $17.9B | $14.3B | $13.7B | $13.2B | $11.0B | $11.5B | $12.2B | $12.8B | $13.5B |
| Total liabilities | $58.1B | $51.9B | $44.9B | $42.4B | $39.6B | $36.4B | $35.4B | $35.4B | $33.6B | $32.8B |
| Shareholders' equity | $33.3B | $17.4B | $14.7B | $14.0B | $10.0B | $10.3B | $7.8B | $7.5B | $5.4B | $7.9B |
| Net debt | $2.3B | $2.7B | $434M | $370M | $1.0B | -$739M | -$692M | -$1.6B | -$1.5B | -$1.7B |
Cash flow
Fiscal years, from Teva Pharma Industries Ltd ADR's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.9B | $2.2B | $2.4B | $748M | $1.2B | $798M | $1.6B | $1.4B | $1.2B | $1.6B |
| Capital spending | $901M | $874M | $651M | $525M | $578M | $562M | $548M | $526M | $498M | $501M |
| Free cash flow | $3.0B | $1.4B | $1.8B | $223M | $638M | $236M | $1.0B | $842M | $749M | $1.1B |
| Stock-based compensation | $124M | $133M | $155M | $119M | $129M | $119M | $124M | $121M | $123M | $157M |
| Dividends paid | $1.3B | $901M | $12M | — | — | — | — | — | — | — |
| Share buybacks (net) | $0 | $0 | — | — | — | — | — | — | — | — |
| Net borrowing | $999M | -$5.0B | -$7.7B | -$3.9B | -$1.9B | -$6.6B | -$1.4B | -$4.2B | -$1.6B | -$4.1B |
| Free cash flow margin | 13.6% | 6.2% | 9.8% | 1.3% | 3.8% | 1.5% | 7.0% | 5.3% | 4.5% | 6.7% |
| Dividends per share | $1,355,879.29 | $0.89 | $0.01 | — | — | — | — | — | — | — |
Questions
What was Teva Pharma Industries Ltd ADR's revenue in 2025?
$17.3B in fiscal 2025, from its 10-K filing.
How much free cash flow does Teva Pharma Industries Ltd ADR generate?
$1.1B in fiscal 2025 (operating cash flow minus capital spending).
From Teva Pharma Industries Ltd ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.